3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
63
Colorectal Neoplasms
30
Biliary Tract Neoplasms
29
Cholangiocarcinoma
27
Pancreatic Neoplasms
26
Liver Neoplasms
18
Stomach Neoplasms
13
Esophageal Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
10
Gallbladder Neoplasms
9
Adenocarcinoma Of Esophagus
9
Neoplasm Metastasis
8
Esophageal Squamous Cell Carcinoma
8
Ovarian Neoplasms
7
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Carcinoma, Renal Cell
6
Carcinoma
6
Bile Duct Neoplasms
6
Triple Negative Breast Neoplasms
5
Rectal Neoplasms
5
Prostatic Neoplasms
5
Colonic Neoplasms
5
Uterine Cervical Neoplasms
4
Lung Neoplasms
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Adenocarcinoma
4
Neoplasms
3
Interventions
Gemcitabine
4
pembrolizumab
3
napabucasin
3
Irinotecan
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
lenvatinib
2
entinostat
2
Taxes
2
Sunitinib
2
Sorafenib
2
Paclitaxel
2
Leucovorin
2
Fluorouracil
2
Cisplatin
2
Bevacizumab
2
pralsetinib
1
linifanib
1
durvalumab
1
Radiofrequency Ablation
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Endoscopic Mucosal Resection
1
Cobicistat
1
Chemoradiotherapy
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
durvalumab
×
Gastrointestinal
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled